Diagnosis & Early Detection/August 19, 2026/2 min read

Hybrid Closed-Loop Systems Help Young Children Better Control Blood Sugar, Study Finds

A systematic review of randomized trials shows that hybrid closed-loop insulin systems significantly improve time in range for children under 7 with Type 1 diabetes, without increasing serious risks.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

diagnosisscreeningautoantibodiesstaging

Key takeaways

Hybrid closed-loop systems helped children under 7 spend about 10% more time in their target blood sugar range after 3 months of use
Average A1C levels dropped by 0.51% with hybrid closed-loop systems compared to conventional therapy
The systems did not increase the risk of diabetic ketoacidosis or severe low blood sugar episodes
This analysis included three randomized controlled trials with 274 children total

What This Study Looked At

Researchers conducted a systematic review and meta-analysis of randomized controlled trials to understand how well hybrid closed-loop systems work for very young children with Type 1 diabetes. Hybrid closed-loop systems are devices that automate some insulin delivery decisions while still requiring some input from the user. The team searched medical databases through July 2025 and analyzed three high-quality trials involving 274 children under age 7.

Key Findings on Blood Sugar Control

After 3 months of use, children using hybrid closed-loop systems spent significantly more time with blood sugar in their target range—about 10 percentage points more than those on conventional therapy. The average A1C, a measure of blood sugar control over time, dropped by 0.51% in the hybrid closed-loop group compared to the conventional therapy group.

However, the study found no meaningful difference between groups in the percentage of time blood sugar dropped below target range, a finding that suggests the systems did not increase low blood sugar episodes.

Safety Profile

The research team examined serious adverse events, including diabetic ketoacidosis (a dangerous buildup of acids in the blood) and severe hypoglycemia (dangerously low blood sugar). There were no statistically significant differences in the risk of either event between children using hybrid closed-loop systems and those receiving conventional therapy, suggesting these systems do not introduce new serious safety concerns for this young age group.

What Comes Next

The authors note that while these results are encouraging, they call for more large-scale, high-quality clinical studies to further confirm and expand on these findings. This kind of ongoing research helps ensure that technology recommendations are based on the strongest possible evidence.

Evidence label

Source: Pediatric diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.